Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy

Anne Bordron (1) , Cristina Bagacean (1, 2) , Audrey Mohr (1) , Adrian Tempescul (3, 1) , Boutahar Bendaoud (1, 2) , Stéphanie Deshayes (1) , Florence Dalbies (3) , Caroline Buors (4) , Hussam Saad (3) , Christian Berthou (1, 3) , Jacques-Olivier Pers (1) , Yves Renaudineau (1, 2)

1 LBAI - Lymphocytes B, Autoimmunité et Immunothérapies
2 Laboratoire d'Immunologie et Immunothérapie [Brest]
3 CHU-Brest-Hemato - CHRU Brest - Service d'Hématologie
4 Labo Hémato - BREST - Laboratoire d'hématologie

Domaines: Sciences du Vivant [q-bio]

Anne Bordron, Cristina Bagacean, Audrey Mohr, Adrian Tempescul, Boutahar Bendaoud, et al.. Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy. Oncotarget, 2018, 9 (60), ⟨10.18632/oncotarget.25657⟩. ⟨hal-01854920⟩